| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ee2b4cf5180521e069e04d91bced4ff1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3092
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-5443
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2086 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0500236afd3b3c16751d2b8739a7cb6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_179c7324c7c4ceffe71cf66357326d60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_075198fe37562b4a67c5e45dc053998d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3b9378e2c7d9d26bb6148c986a8e2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3aad1454a09eae99da20bbeb797a9f9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df2ad3d29ef6546bcd74efde8538d993 |
| publicationDate |
2020-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
BR-112020015202-A2 |
| titleOfInvention |
CONSTRUCTIONS OF FUSION PROTEINS UNDERSTANDING AN ANTIBODY ANTI-MUC1 AND IL-15 |
| abstract |
The present invention relates to fusion protein constructs comprising an antibody against the cancer antigen MUC1 and IL-15. In particular, the fusion protein constructs activate NK cells and T cells at the cancer site. |
| priorityDate |
2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |